key: cord-0752859-cm0o3bbb
authors: Elliott, Eric Isaac; Wang, Andrew
title: Interferon gamma runs interference on persistent COVID-19
date: 2021-10-08
journal: Med (N Y)
DOI: 10.1016/j.medj.2021.09.004
sha: 19dae0ac1c9eec991e994daaa20be539ae4d8a6d
doc_id: 752859
cord_uid: cm0o3bbb

COVID-19 represents a collection of disease endotypes stemming from infection with SARS-CoV-2 and thus requires precision medicine approaches to target specific viral variants and stages of illness. In this issue, van Laarhoven et al.(1) describe five immunocompromised patients with prolonged COVID-19 successfully treated with interferon gamma (IFNγ).

The concept of endotype, first coined in 1966, has since been widely applied to diverse human diseases. 2 Fundamentally, the concept of endotype recognizes that diverse underlying mechanisms of pathogenesis produce the same clinically defined (easily observable) disease features. This framework partially explains why diseases lack uniform response to therapy. Like other infectious diseases, COVID-19 encompasses many endotypes which manifest as asymptomatic carriage, mild respiratory illness, acute respiratory distress syndrome (with low and high elasticity phenotypes), sepsis syndrome, and hyperinflammatory syndromes resembling macrophage activation syndrome/hemophagocytic lymphohistiocytosis (multisystem inflammatory syndrome in children [MIS-C] and adults [MIS-A]). The diverse endotypes are posited to be a function of variant and load of SARS-CoV-2 inoculum, host-intrinsic genetic/epigenetic characteristics, and unknown ''environmental'' determinants. 3 While complex, COVID-19 pathogenesis can be broadly conceptualized as failures in viral control (disease resistance) and failures in tolerating immunologic and non-immunologic aspects of host response to infection (disease tolerance) 4 ( Figure 1A ). These factors operate dynamically along different stages of disease and as a function of medical interventions.

Immunocompromised individuals are a heterogenous population of patients with severely impaired disease resistance who are uniquely vulnerable to poor COVID-19 outcomes. 5 The immune response necessary to achieve viral clearance of SARS-CoV-2 requires multiple intact and coordinated immune effector functions, among which there are multiple points of failure and opportunities for targeted intervention. 6 For example, as humoral immunity is essential for effective viral clearance and survival, passive immunization has repeatedly shown benefit in the subset of immunocompromised patients with defective humoral responses who may not have other comorbid immune failures. Herein, van Laarhoven and colleagues present a series of five immunocompromised patients with prolonged, severe COVID-19, unresponsive to commonly used enhancers of disease tolerance and resistance, who ultimately improved with IFNg administration 1 ( Figure 1B) . This report is a prime example highlighting the growing awareness for the need of host-and mechanism-directed therapies (precision medicine) in managing COVID-19 and other sepsis syndromes.

The case series details five immunocompromised patients with prolonged, severe COVID-19. Two (patients 1 and 4) with underlying conditions impairing humoral immune responses (e.g., common variable immunodeficiency) were also noted clinically to have defective cellular immunity following SARS-CoV-2 infection as evidenced by HSV reactivation and invasive pulmonary aspergillosis. The other three patients were renal transplant recipients who received B cell-depleting agents that impair humoral immunity (e.g., rituximab or alemtuzumab) but were also on therapies-tacrolimus, mycophenolate mofetil, and corticosteroids-that generally impair immune function including T cell responses. Unsurprisingly, application of the current panoply of COVID-19 therapies, variably directed at disease resistance (passive immunization and remdesivir) and tolerance (dexamethasone and tocilizumab), did not impact clinical trajectory. Van Laarhoven and colleagues thus decided to augment cellular mechanisms of pathogen clearance by administering IFNg. Following IFNg, all five patients experienced reduction in detectable SARS-CoV-2 that corresponded to improved respiratory status. Four patients were discharged from intensive care, and three were extubated. Because immunopathology represents one endophenotype of COVID-19 thought to be IFNg-driven, van Laarhoven et al. were vigilant that IFNg may provoke a hyperinflammatory response but found no uniform evidence of worsened systemic inflammation. 1 IFNg is approved for treatment of chronic granulomatous disease and malignant osteopetrosis and has been used in patients with HIV, mycobacterial infections, invasive fungal infections, and malignancies 7 . A role for exogenous IFNg in COVID-19 is biologically plausible, as patients with COVID-19 have T cell lymphopenia, CD4 responses skewed away from T H 1, CD8 senescence, and impaired IFNg production 8 . Several other groups have used IFNg in patients with COVID-19. As in this series, Lukaszewicz et al. found IFNg improved SARS-CoV-2 clearance and clinical status in a patient with rheumatoid arthritis and Sjö gren syndrome on rituximab who had worsened despite convalescent plasma 9 . A patient with endogenous anti-IFNg antibodies was treated for COVID-19 with plasma exchange and exogenous IFNg, but interestingly he did not have severe COVID-19 symptoms. 10 HLA-DR expression may be useful as a biomarker to define an endotype that benefits from IFNg, as IFNg restored monocyte activation and improved ventilator-associated pneumonia in otherwise immunocompetent COVID-19 patients with decreased monocyte HLA-DR 11 . However, as one would predict from the U-shaped biology of IFNg ( Figure 1A) , studies are conflicting in terms of whether greater IFNg production is associated with worsened outcomes in severe COVID-19. Indeed, the anti-IFNg monoclonal antibody emapalumab is being investigated in clinical trials (NCT04324021).

This present case series is limited by small numbers and observational design without controls. Another limitation of this study is that a mechanistic link from IFNg to augmented cellular immunity and viral clearance is not definitively established. Prior to IFNg administration, viral cultures were negative in patients 1 and 3, inconsistently positive in patient 2, and not performed for patients 4 and 5. As PCR detection of viral RNA may not represent infectious virus, it is uncertain whether IFNg is beneficial due to augmented disease resistance via viral clearance or by another mechanism. Rather, IFNg may improve clearance of inflammatory but noninfectious viral pathogen-associated molecular patterns or contribute to other mechanisms of disease tolerance. Nonetheless, the clinical decision-making process and arrival at therapeutic IFNg highlights the need for a precision approach to COVID-19 specifically, and to sepsis syndromes in general.

As disease endotypes are better defined, aided by technologic advances and spurred by wider recognition that clinically defined diseases are comprised of an array of complex pathophysiologic phenotypes that require multidisciplinary approaches, we have observed advances in the medical management of psychiatric illness, autoimmunity, asthma, cancer, and other conditions. The COVID-19 pandemic presents scientists with an unprecedented opportunity to define and understand endotypes of infectious disease. ''Targeted'' therapies will likely be reliable only in certain subsets of patients (their respective ''targets'') and identifying clinical factors and biomarkers that define endotypes of COVID-19 will aid clinical trial design and improve likelihood of successful outcomes. For COVID-19, the question remains who should we treat, what with, and when? A B Figure 1 . COVID-19 disease is composed of several incompletely defined endotypes Endotypes can be broadly characterized as failures in disease resistance, such as inborn or acquired defects in pathogen clearance, and/or failures in disease tolerance, such as exuberant inflammatory responses or impaired tolerance to inflammatory damage, which both lead to increased probability of death from SARS-CoV-2 infection. (A) Failure to produce sufficient IFNg, for example, leads to defects in pathogen clearance, while failure to restrain IFNg production leads to immunopathology. (B) Immunosuppressive medications target hyperinflammatory disease endotypes while passive immunization promotes viral clearance in patients with defective humoral immunity. Van Laarhoven et al. 1 utilized IFNg to target likely defects in cellular immunity when treatments targeting humoral immunity and hyperinflammation failed.

Interferon gamma immunotherapy in five critically ill COVID-19 patients with impaired cellular immunity: a case series

Chromosome variability and geographic distribution in insects

Precision Medicine for COVID-19: Phenotype Anarchy or Promise Realized?

Disease tolerance as a defense strategy

Improving the Outcomes of Immunocompromised Patients With Coronavirus Disease

Immune determinants of COVID-19 disease presentation and severity

Clinical Use of Interferon-gamma

MGH COVID-19 Collection & Processing Team (2021). Type I, II, and III Interferon Signatures Correspond to Coronavirus Disease

Immunostimulation with interferon-g in protracted SARS-CoV-2 pneumonia

Neutralizing Anti-interferon-g Autoantibodies: an Ameliorating Factor in COVID-19 Infection?

Potential role for interferon gamma in the treatment of recurrent ventilator-acquired pneumonia in patients with COVID-19: a hypothesis

We thank the Wang Lab for valuable discussions. A.W. is supported in part by NIH grants 1K08AI128745 and R01 AI162645 as well as the Pew Charitable Trusts, the Knights of Columbus, the G. Harold and Leila Y. Mathers Foundation, and the Ludwig Family Foundation. E.E. is supported by NIH grant 5T32AI007517.

The authors have no conflicts of interest to declare.